ISEH 2025 | Professor Toshio Suda on the Core Highlights of the Conference and the Frontiers of Hematopoietic Stem Cell Research

ISEH 2025 | Professor Toshio Suda on the Core Highlights of the Conference and the Frontiers of Hematopoietic Stem Cell Research

2025.10.14
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan. As one of the most prestigious international conferences in the field of hematology, this year’s meeting gathered leading experts from around the world to engage in in-depth discussions on the latest advances in basic hematology, immunology, stem cell research, and cell and gene therapy. During the conference, Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Toshio Suda, former President of ISEH and Distinguished Professor at Peking Union Medical College, who shared his insights on the major highlights of the meeting and the latest developments in stem cell research.
ISEH 2025 | Professor Fumio Arai: Regulatory Mechanisms of Hematopoietic Stem Cell Quiescence and Their Clinical Translation Prospects

ISEH 2025 | Professor Fumio Arai: Regulatory Mechanisms of Hematopoietic Stem Cell Quiescence and Their Clinical Translation Prospects

2025.10.14
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan, bringing together leading global experts in hematology to discuss cutting-edge advances in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the major highlights of the event was the Sino-Japanese Joint Symposium on Stem Cells and Cellular Therapy, which drew wide attention. At the symposium, Professor Fumio Arai from Kyushu University, Japan, delivered an insightful presentation titled “Signaling networks governing hematopoietic stem cell quiescence.” In this interview, Oncology Frontier – Hematology Frontier invited Professor Arai to discuss the role of signaling networks in maintaining stem cell function and their potential in clinical applications.
ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy

ISEH 2025 | Professor Tao Cheng: Revitalizing Sino-Japanese Hematology Exchange and Exploring the Frontiers of Cell and Gene Therapy

2025.09.30
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27 in Kumamoto, Japan. This prestigious event brought together leading experts from around the world to discuss cutting-edge developments in basic hematology, immunology, stem cell research, and cell and gene therapy. One of the highlights of this year’s meeting was the “Sino-Japanese Joint Symposium on Stem Cells and Cellular Therapy,” co-organized by the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), and Kumamoto University, marking the successful restart of the Sino-Japanese academic exchange mechanism. During the conference, Oncology Frontier – Hematology Frontier invited Professor Tao Cheng of the Institute of Hematology & Blood Diseases Hospital to share his insights on the origins of this joint symposium, the hottest frontiers in the field, and opportunities for young researchers to engage internationally.
ISEH 2025 China–Japan Dialogue | Prof. Jianxiang Wang and Prof. Naoki Hosen: Direct Insights into CAR-T Therapy for Leukemia and a New Blueprint for International Collaboration 

ISEH 2025 China–Japan Dialogue | Prof. Jianxiang Wang and Prof. Naoki Hosen: Direct Insights into CAR-T Therapy for Leukemia and a New Blueprint for International Collaboration 

2025.09.29
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held in Kumamoto, Japan, from September 24–27. The conference brought together leading experts in hematology from around the world to discuss cutting-edge progress in basic hematology, immunology, stem cell research, and cell and gene therapies. During the meeting, Oncology Frontier – Hematology Frontier invited Professor Jianxiang Wang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, and Professor Naoki Hosen from Osaka University for a deep dialogue on the latest advances in CAR-T therapy for leukemia. Their discussion covered multiple dimensions — from basic mechanisms and clinical applications to efficacy optimization and future directions — with the shared goal of promoting innovation in CAR-T therapy, advancing international collaboration, and improving global patient access and outcomes.